Age group (In Yrs) |
Study |
Control |
||||
Male |
Female |
Total |
Male |
Female |
Total |
|
40-60 |
11 (22%) |
19 (38%) |
30 (60%) |
10 (20%) |
12 (24%) |
22 (44%) |
61+ |
12 (24%) |
8 (16%) |
20 (40%) |
16 (32%) |
12 (24%) |
28 (56%) |
Total |
23 (46%) |
27 (54%) |
50 (100%) |
26 (52%) |
24 (48%) |
25 (100%) |
Age group (In Yrs) |
Study group |
Control group |
Total |
||||
White MSC |
Total |
Nuclear |
PSC |
Cortical |
Mixed |
||
40-60 |
25 (50%) |
25 (50%) |
0 (0%) |
7 (14%) |
13 (26%) |
2 (4%) |
22 (44%) |
61+ |
25 (50%) |
25 (50%) |
9 (18%) |
2 (4%) |
8 (16%) |
9 (18%) |
28 (56%) |
Total |
50 (100%) |
50 (100%) |
9 (18%) |
9 (18%) |
21 (42%) |
11 (22%) |
50 (100%) |
Intraoperative complications |
Study group |
Control group |
χ2 |
P-value |
Significance |
||||
Present |
Absent |
Total |
Present |
Absent |
Total |
||||
Detachment of descemet's |
0 (0%) |
50 (100%) |
50 (100%) |
0 (0%) |
50 (100%) |
50 (100%) |
- |
- |
- |
Wound site thermal injury |
0 (0%) |
50 (100%) |
50 (100%) |
0 (0%) |
50 (100%) |
50 (100%) |
- |
- |
- |
Zonulodialysis |
1 (2%) |
49 (98%) |
50 (100%) |
1 (2%) |
49 (98%) |
50 (100%) |
0.00 |
> .05 |
NS |
Capsulorrhexis ext. |
2 (4%) |
48 (96%) |
50 (100%) |
1 (2%) |
49 (98%) |
50 (100%) |
0.033 |
> .05 |
NS |
Posterior capsule rent |
1 (2%) |
49 (98%) |
50 (100%) |
1 (2%) |
49 (98%) |
50 (100%) |
0.00 |
> .05 |
NS |
Cornea |
Days |
|||||||||
1 |
3 |
7 |
30 |
45 |
||||||
Study |
Control |
Study |
Control |
Study |
Control |
Study |
Control |
Study |
Control |
|
Bright |
46 (92%) |
49 (98%) |
46 (92%) |
50 (100%) |
48 (96%) |
50 (100%) |
50 (100%) |
50 (100%) |
50 (100%) |
50 (100%) |
Stromal edema |
4 (8%) |
1 (2%) |
4 (8%) |
0 (0%) |
2 (4%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
χ2 |
0.842 |
- |
- |
- |
- |
|||||
P-value |
> .05 |
- |
- |
- |
- |
|||||
Significance |
NS |
- |
- |
- |
- |
|
Group |
P-value |
Significance |
|
Study |
Control |
|||
Mean ± Sd |
32 ± 9.97 |
18.24 ± 13.36 |
< .001 |
Highly significant |
Group |
Mean ± Sd Postoperative day |
|||||
Pre-OP |
1 |
3 |
7 |
30 |
45 |
|
Study |
15.19 ± 1.59 |
17.50 ± 1.99 |
16.72 ± 1.82 |
15.54 ± 1.49 |
15.01 ± 1.58 |
14.76 ± 1.64 |
Control |
14.01 ± 1.38 |
15.89 ± 1.57 |
15.77 ± 1.44 |
14.75 ± 1.32 |
14.38 ± 1.29 |
13.63 ± 1.15 |
BCVA |
Day |
|||||||||
1 |
3 |
7 |
30 |
45 |
||||||
Study |
Control |
Study |
Control |
Study |
Control |
Study |
Control |
Study |
Control |
|
6/18 |
11 (22%) |
8 (16%) |
- |
- |
- |
- |
- |
- |
- |
- |
6/12 |
12 (24%) |
10 (20%) |
15 (30%) |
10 (20%) |
6 (12%) |
4 (8%) |
6 (12%) |
4 (8%) |
5 (10%) |
4 (8%) |
6/9 |
16 (32%) |
20 (40%) |
15 (30%) |
13 (26%) |
15 (30%) |
13 (26%) |
11 (22%) |
9 (18%) |
10 (20%) |
8 (16%) |
6/6 |
11 (22%) |
12 (24%) |
20 (40%) |
27 (54%) |
29 (58%) |
33 (66%) |
33 (66%) |
37 (74%) |
35 (70%) |
38 (76%) |
Total |
50 (100%) |
50 (100%) |
50 (100%) |
50 (100%) |
50 (100%) |
50 (100%) |
50 (100%) |
50 (100%) |
50 (100%) |
50 (100%) |
P- value |
> 0.05 |
> 0.05 |
> 0.05 |
> 0.05 |
> 0.05 |
|||||
Sig. |
NS |
NS |
NS |
NS |
NS |